Otsuka Pharmaceutical Co. Ltd.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Otsuka Pharmaceutical Co. Ltd.
These are interesting times for Mironid, a Glasgow-based biotech developing small molecule therapeutics for the treatment of autosomal dominant polycystic kidney disease, a life-threatening hereditary condition.
Otsuka steps into the ocular gene therapy field through a technology licensing deal worth up to $1.5bn with ShapeTX, which in turn further expands the US firm's global reach following a $3bn collaboration with Roche.
Click Therapeutics And Indivior Collaborate On Prescription Digital Therapeutics In Substance Use Disorder
Click Therapeutics and Indivior will develop a digital solution for treating substance use disorders, starting with opioid use disorders. Click already signed partnership deals with Otsuka and Verily and Boehringer Mannheim to co-develop digital therapeutics for patients with schizophrenia and major depressive disorder.
After a year of R&D collaboration, Otsuka has made a decision to acquire Canadian venture Mindset to further expand its neurological pipeline with new 5-HT2A agonists.
- Medical Devices
- OTC, Consumer
In Vitro Diagnostics
- Chemistry, Immunoassay
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.